About Us

Leading the Transformation of Science into Novel Immunotherapies

Our leadership team brings a strong record in all facets of the industry that are necessary to safely and efficiently develop immunotherapeutic candidates. We have a unique combination of large pharmaceutical experience and entrepreneurial successes that allows us to access a depth of experience and expertise in areas from clinical research and regulatory reviews, to expanding business development and commercialization opportunities. At the same time, we retain the nimble sprit of a smaller organization that can react effectively to new opportunities. Above all, our dedication to making immunotherapies more effective, more broadly applicable and more widely available to people facing cancer and other serious diseases underscores the work we do every day.

Frederic “Fred” Ors

Chief Executive Officer

Fred has served as our Chief Executive Officer since April 2016. As CEO, he has led the transformation of IMV into a leading clinical-stage immune-oncology company with world-class collaborators and a strong scientific foundation. He has more than 21 years of experience in the biopharmaceutical industry, having served in several management positions encompassing business development, intellectual property, strategic planning, pre-marketing, and communication. Before joining IMV, Fred spent 14 years at Medicago serving in many roles of increasing responsibility, most recently as Vice President of Business Development and Strategic Planning. He had been an integral part of Medicago’s success, including securing more than $300M CAN in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts, and the $357M CAN deal acquisition by Mitsubishi Pharma in 2013.

Fred is also a Director of CQDM, a biopharmaceutical research consortium and served as second Vice-Chair of the Vaccine Industry Committee of Biotech Canada between 2012 and 2016. Prior to Medicago, Fred was Licensing Manager at the University Paris VII-Denis Diderot, one of the largest sciences and medical university in France. He owns a BSc degree in Biology and a Master’s degree in Biotechnology and Business Management from the University of Angers (France).

Back to Top

Pierre Labbé

Chief Financial Officer

Pierre is Chief Financial Officer of IMV since February 2017. He has more than 25 years of progressive financial leadership roles in various industries. Before joining IMV, he was Vice President and Chief Financial Officer of Leddartech Inc., a leader in lidar for the automotive industry. His experience in the life sciences sector includes serving as Chief Financial Officer and secretary of Medicago Inc. until the completion of the privatization of Medicago Inc., following the acquisition by Mitsubishi Pharma for an enterprise value of $357M CAN in 2013. In his career as a senior financial officer, he has participated in the development of strategic plans, financing and mergers and acquisitions (over $1 billion CAN in transactions).

Pierre is also a Director of Osisko Gold Royalties Ltd. (OR: TSX & NYSE). He holds a Bachelor’s Degree in Business Administration and a license in accounting from Université Laval, Québec City. Pierre is a member of Ordre des comptables professionnels agréés du Québec, the Chartered Professional Accountants of Canada and the Institute of Corporate Directors.

Back to Top

Joanne Schindler, MD

Chief Medical Officer

Joanne brings over 15 years of experience in the biopharmaceutical industry, primarily in early-stage oncology drug development. Most recently, she served as Vice President, Clinical Development and Executive Medical Director at H3 Biomedicine, overseeing the company’s clinical development efforts. Previously, she worked as Vice President, Clinical Development at Constellation Pharmaceuticals, and earlier held various clinical development leadership roles at SynDevRx, ImmunoGen, Novartis, Fresenius Biotech and GlycoGenesys. Over the course of her career, Joanne has played an instrumental role in advancing novel programs into the clinic, as well as the development and execution of clinical strategy.

Joanne holds an M.D. from the University of Connecticut School of Medicine, a D.V.M. from Tufts University School of Veterinary Medicine and a B.A. in biology from Brandeis University.

Back to Top

Joseph Sullivan

Senior Vice President, Business Development

Joseph brings over 25 years of global pharmaceutical and vaccine industry experience to IMV. Prior to joining the Company, he worked at Merck & Company, Inc., launching new products and indications, evaluating business development opportunities, and forming external collaborations. Most recently, Joseph led cross-functional efforts to identify, negotiate, and operationalize global vaccine partnerships to expand market access. Preceding this position, he led the New Vaccines Product Group, which was responsible for the commercial direction of new vaccine development, evaluation of product licensing candidates, and preparing pre-launch marketing plans.

Joseph provides IMV with a significant breadth of commercial experience, including the introduction of Merck’s Gardasil® in the US, and the market expansion of Singulair® into the asthma and allergic rhinitis markets. Prior to his tenure at Merck, he was an Associate in Venture Capital & Investment Banking with Allen & Company Inc., and completed the financial management training program at GE Company. Joseph earned his MBA from Cornell University and a BA from Hamilton College.

Back to Top

Stéphan Fiset

Vice President, Clinical Research

Stephan manages the implementation and progress of IMV’s clinical programs. Prior to joining the company, he worked for more than 15 years in clinical research with Medicago, GlaxoSmithKline and the Infectious Disease Research Center of the CHUL, where he led multifunctional teams in several therapeutic areas, including Oncology, HIV, Vaccines, Sepsis, Hematology, and Neurology. Throughout his career, he was involved in scientific and operational activities of several Phase I to Phase III trials. He has also led several process improvement teams to ensure timely and cost-effective delivery of clinical trials. Stephan received an MBA with honor from Université Laval and a Master degree in Microbiology from the University of Sherbrooke.

Back to Top

Marianne Stanford, PhD

Vice President, Research & Development

Marianne oversees all preclinical research activities and clinical immunology assessment of cancer immunotherapies and infectious disease vaccines. She also serves as adjunct professor in Microbiology and Immunology at Dalhousie University, as a member of the Vaccine Discovery group of the Canadian Centre for Vaccinology, and as an Associate Member of the Beatrice Hunter Cancer Research Institute. Before joining the Company in 2010, Marianne conducted her postdoctoral training at the Robarts Research Institute and at the Ottawa Hospital Research Institute (OHRI), focusing her research on the use of viruses in the development of novel cancer treatments. While at the OHRI, she worked with Jennerex Biotherapeutics (now SillaJen) in the development of Pexa-Vec for human clinical trials. She received her BSc and MSc from Memorial University of Newfoundland and her PhD from Dalhousie University. In her spare time, Marianne is involved in science outreach and policy and is the former Chair of the Canadian Association of Postdoctoral Scholars.

Back to Top

Annie Tanguay

Vice President, Quality and Regulatory

Annie is responsible for development, implementation and maintenance of IMV’s Quality systems, programs and processes to ensure GXPs compliance. She brings more than 27 years of experience in pharmaceuticals and biopharmaceuticals industries to IMV, serving over half of these years in multinational pharmaceutical companies involved in Sterile Products manufacturing. During a 10-year career at Abbott Laboratories, she served in many Quality roles with increasing responsibilities, from Quality Control (QC) laboratory supervisor to Plant Compliance Manager. Prior to joining IMV, she spent almost 15 years at Telesta Therapeutics (formerly known as Bioniche Life Sciences), where she held the position of Quality Director at the Montreal manufacturing facility, which specialized in Sterile Biologic Manufacturing. She was responsible for development and implementation of the Quality Manufacturing Systems (QMS) at the facility, set-up of QC laboratories and overall GMP site compliance. She has actively participated in meetings with regulatory agencies (FDA and Health Canada BGTD) and has hosted several GMP inspections. She holds a BSc in Microbiology from Laval University in Quebec.

Back to Top

Back to Top